Treatment with interleukin-22 (IL-22) [24, 25], R-spondin [26, 27] and glucagon like peptide-2 (GLP-2) [28] led to improved intestinal regeneration and reduced GVHD related mortality in mice. The gene discussed is GCG; the disease is graft versus host disease.